GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AGIO · Jun 30, 2025

AGIOS PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001439222-25-000089General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

7.03% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-619.22% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

44.57% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

247.68% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

86.33% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-1020.12% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

738.18% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

117.96% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History9 statesHistory building

Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/7 normalizedLevel 3 Jun 30, 20250/8 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/8 normalizedLevel 3 Mar 31, 20260/8 normalizedLevel 3 Jun 30, 20267/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Decreased

Previous: 8.78%
Current: 7.03%
Delta: -1.75%

Cash Generation Increased

Previous: -1277.66%
Current: -619.22%
Delta: 658.44%

Inventory Pressure Decreased

Previous: 339.27%
Current: 247.68%
Delta: -91.60%

Margin Decreased

Previous: 87.57%
Current: 86.33%
Delta: -1.23%

Profitability Increased

Previous: -1221.97%
Current: -1020.12%
Delta: 201.85%

R And D Intensity Decreased

Previous: 833.64%
Current: 738.18%
Delta: -95.46%

Sbc Intensity Decreased

Previous: 130.17%
Current: 117.96%
Delta: -12.21%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · AGIO Fundamental State →Transitioned To · AGIO Fundamental State →Transitioned To · AGIO CAPEX_INTENSITY_DECREASED →Transitioned To · AGIO CASH_GENERATION_INCREASED →Transitioned To · AGIO INVENTORY_PRESSURE_DECREASED →Transitioned To · AGIO MARGIN_DECREASED →Transitioned To · AGIO PROFITABILITY_INCREASED →Transitioned To · AGIO R_AND_D_INTENSITY_DECREASED →Transitioned To · AGIO SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.